In the patients who received previous concurrent chemoradiotherapy , median overall survival for the @ ( @ % ) of @ patients assigned to tecemotide was @ months ( @ % CI @-@ @ ) compared with @ months ( @-@ @ ) for the @ ( @ % ) of @ patients assigned to placebo ( adjusted HR @ , @-@ @ ; p = @ ) .